Emerging literature has discussed the possibility of glypicans as both diagnostic markers and therapeutic targets for cancer (Filmus and Capurro, 2013; Bosse et al., 2017; Fu et al., 2018; Li et al., 2018). Here, GPC1 is linked to cancer.